The fact that leukaemic cells are primarily or secondarily resistant to cytostatics is a serious phenomenon, which leads to the failure of chemotherapy of malignant diseases in clinical practise. Some detoxification and transporting systems are responsible for the generation of chemoresistance on the cellular level and the decrease of effectiveness in treatment.
Introduction
Chemotherapy is the dominant method for the treatment of systemic malignant diseases, like leukaemia or lymphoma. It inhibits proliferation of leukaemic cells by using cytostatics (chemotherapeutics). The treatment in malignant haematologic diseases results in an initial response in the majority of patients. However, the remission may be of short duration and is frequently followed by a relapse of resistant tumour cells associated with clinically refractory disease. Drug resistance (chemoresistance) is a major problem that limits the effectiveness of chemotherapies used to treat haematological malignancies (HMs). Goldie & Coldman (1983) have formulated that tumour cells may be resistant to chemotherapy prior to treatment due to spontaneous mutations. These cells expand by selection during treatment and overgrow the sensitive cells (Goldie & Coldman 1983) .
In addition to intrinsically resistant cells, multidrug resistance (MDR) can develop during treatment. Recently, the existence of the so-called pleiotropic drug resistance has been identified (Goldstein et al. 1989; Borst 1991) . MDR is present in the situation where the tumour cell is insensitive to many cytostatics, and is different in chemical structure and/or the mechanism of action (Hatok et al. 2006; Stavrovskaya & Stromskaya 2008) . Drug resistance mechanisms consist of cellular factors, such as induction of specific enzymes, modulation of drug receptor expressivity, drug resistance phenomenon, etc., and non-cellular factors like biotransformation, cell kinetics, inadequate perfusion of tumour mass, etc. (Hedley et al. 1993; Di Paolo & Bocci 2007) . Although it is assumed that cellular drug resistance largely determines the prognosis, little is known about the clinical forms and mechanisms of drug resistance in different malignant diseases (Hajduch et al. 1996) . The main reason for this was the absence of an appropriate method for an in vitro drug resistance assay in clinical practice. Therefore, Veerman & Pieters (1990) in-troduced the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazoline (MTT) assay for analysis of leukaemic cell chemoresistance. The MTT assay can identify resistance independent of the mechanism involved and provides a means to screen for effective resistance modification. We adapted the original assay for drug resistance testing of leukaemic cells. The goal of the study was to test chemoresistance of leukaemic cells to the spectrum of cytostatics and to compare results of the in vitro chemoresistance between different types of HMs. We also compared the in vitro chemoresistance between paired leukaemic cells from peripheral blood (PB) and bone marrow (BM).
Material and methods

Cells
Heparinized bone marrow (BM) or peripheral blood (PB) samples were obtained from 71 adult patients with leukaemia (age 19-84 years). These patients consisted of 28 with initial acute myeloid leukaemia (AML), 10 with initial acute lymphoblastic leukaemia (ALL), 2 with initial chronic myeloid leukaemia (CML), 17 with relapsed AML, 8 with relapsed ALL and 6 with relapsed CML. Blast cells were isolated by centrifugation in Ficoll gradient (density 1.077 g/mL) (Lymphocyte Separation Medium LSM 1077; PAA Laboratories GmbH, Austria) for 25 min at 2200 rpm. After isolation the cells were washed twice and re-suspended in RPMI 1640 culture medium (Dutch modification, Gibco, USA) supplemented with 15% heatinactivated foetal bovine serum, 2 mM L-glutamine, 100 IU/mL penicillin, 100 µg/mL streptomycin and 0.005% insulin-transferrin-sodium selenite at 37
• C in a humidified incubator containing 5% CO2. The samples with ≥ 75% leukaemic (blast) cells at the start of the culture were studied. The cell viability was determined by trypan blue dye exclusion.
Chemoresistance assay
We used the colorimetric MTT assay described by Black & Speer (1953) , while Mosmann (1983) described the MTT assay in its present semi-automated form. It is based on the fact that living cells, in contrast to dead cells, can reduce MTT into a colored formazan product. Briefly, leukaemic cells were cultured in the 96 well microculture plates for 3 days at a final concentration of 1.0-1.5×10
6 cells/mL, with or without cytotoxic agents. The 71 leukaemic samples were tested with up to 15 drugs, depending on the amount of cells available: 6-mercaptopurine (6-MP, concentration range: 78.12-2.500 µg/mL), 6-thioguanine (6-TG, 50-1.5625), cytarabine (Ara-C, 20-0.01953), cladrabine (2-CdA, 40-0.0004), dacarbazin (Dak, 500-0.4883), daunorubicin (Dau, 2-0.00195), dexamethasone (Dex, 6-0.0002), doxorubicin (Dox, 2-0.00195), etoposide (VP-16, 50-0.04883), idarubicin (Ida, 2-0.0019), metylprednisolone (m-Pred, 1498-0.04571), mitoxantrone (Mix, 2-0.00195), prednisolone (Pred, 1250-0.03815), vinblastine (Vnb, 50-0.04883), vincristine (Vnc, 50-0.04883). Concentrated stock solutions of cytostatics were stored at −20
After 72 h of incubation, 10 µL MTT solution (5 mg/mL) was added to each cell and the plates were incubated for further 6 h. The produced formazan was solubilized by adding 100 µL lysing buffer of 10% sodium dodecyl sulfate (SDS), pH = 5.0. After an overnight incubation at 37
• C, the optical densities (OD) at 540 nm were measured using a microplate reader (Bio Rad Reader 2100). Cells incubated in a culture medium alone served as a control for cell viability (untreated cells). All assays were performed in quadruplicate and mean ± SD values were used to estimate cell viability. The cell survival (CS) was calculated by the equation: CS = (OD treated cell/mean OD control cells) × 100%. The LC50, the cytostatic concentration required to kill 50% of the cells as compared to the control cell survival was calculated from the dose-response curve used by the software Chemoresistance 2.0 (Brno, Czech Republic).
Statistics
The correlation among LC50 values of different drugs and groups of patients were estimated using non-parametric Wilcoxon matched pairs signed ranks and Student T-test. The statistical level of significance was set to two-tiled P ≤ 0.05. All statistical calculations were performed using the statistical package MedCalc 8.1.1 (MedCalc Inc. , Belgium). The linear regression analysis was used to determine the strength of the relationship between LC50-PB and LC50-BM by OriginPro 7 SR2 software (OriginLab Corporation, USA). The strength of this relationship was defined by using R value (Pearson's correlation coefficient).
Results
The percentage median of living leukaemic cells in the control cells was 95% (range, 85-100%) at the start of the culture, and 72% (range, 49-116%) at the end of the 3-day incubation period. The median of optical density in the control cells without cytostatics after 3 days of cultivation was for the ALL samples 0.175 (0.091-0.412), for the AML samples 0.327 (0.263-0.830), and for the CML samples 0.354 (0.298-0.520). Samples from 31 males and 40 females were investigated. In general, gender was not significantly related to drug resistance. All samples contained more than 75% blast. We compared the range and median of LC 50 values of each drug for all leukaemic BM samples and all leukaemic PB samples from 71 patients with HM. No significant differences were found between BM and PB leukaemic cells in resistance to any of the investigated drug. In 8 cases (4 AML, 4 ALL) drug resistance results from paired BM and PB samples were studied. Analysis of these paired data also showed no preferential resistance of BM or PB leukaemic cells to any of the drugs. There was a positive correlation (R = 0.9844; P < 0.0001) between the paired BM and PB LC 50 values in most individual cases and in the 42 paired BM and PB LC 50 comparisons together (Fig. 1) .
On the basis of the chemoresistance curve it was possible to determine the resistance of leukaemic cells to cytostatics in patients (Fig. 2) . Figure 2 shows the dependence of cell survival (% of control) on the increased concentration of cytostatics (µg/mL). The dashed line (Fig. 2) indicates concentration of cytostatic killing 50% of leukaemic cells (LC 50 ). If the cytostatic at high concentration decreases the ratio of survival of leukaemic cells under 25%, these cells are sensitive to the cytostatic ( Fig. 2; daunorubicin) . The highest concentration of cytostatics is the killing of more than 25% but less than 50% of leukaemic cells; such cells are evaluated as intermediately sensitive (responsive). When the population of leukaemic cells survives at higher concentration of cytostatics, then the response to the in vitro testing of chemoresistance is evaluated as resistant ( Fig. 2 ; dexamethasone).
We have compared the median LC 50 values of each drug for all leukaemic BM samples and all leukaemic PB samples from 71 patients with different diagnoses (Table 1) . We have found some significant differences between AML and ALL. The group of AML samples (n = 45) showed higher LC 50 values for cladrabine, dexamethasone, etoposide, metylprednisolone, mitoxantrone, prednisolone, vinblastine and vincristine than did the ALL samples (n = 18). For dexamethasone, etoposide, prednisolone and vincristine, the differences were statistically significantly different (Table 1) . The ALL samples were less sensitive to cytarabine, daunorubicin and doxorubicin than the AML samples, but the result almost reached significance. Lymfoblasts from the CML patients did not differ significantly in resistance from the patients of AML and ALL for all tested drugs. We also compared drug resistance profiles according to the immunophenotype of blasts. There were no significant differences in drug resistance between immuphenotype of AML (8 M0, 5 M1, 5 M2, 4 M3, 7 M4, 6 M5 and 2 M6). Adult T-ALL (n = 9) also did not differ significantly in drug resistance from the adult B-ALL (n = 9).
Discussion
Despite many attempts to identify a reliable prognostic indicator in HMs, e.g. blast cells morphology, cytogenetics and proliferative potential, none fulfils the criteria fully. While each method has relevancy in the prediction of remission, induction is multifactorial and involves many risk elements (Elgie et al. 1996) . We have attempted to utilize a simple, reproducible and noninvasive technique to measure the metabolic activity of the cell. We have compared results of in vitro drug resistance among different diagnoses of HMs.
The MTT assay provides a rapid assessment of drug resistance. Principally, it is a short-term culture assay that is nonradioactive (Hansen et al. 1989; Dogan et al. 2004 ). On the other hand, this assay is unable to evaluate the cytostatic effect of chemotherapeutic drugs (te Boekhorst et al. 1993) . Measuring the capacity of viable cells to reduce tetrazolium salt into a formazan product quantifies cellular damage due to cytotoxicity. In our experiments with various drugs, 72 hours of incubation was chosen for precise evaluation of cytotoxicity and/or chemoresistance. Incubation duration was also considered for the survival of control cells.
We demonstrated, using the MTT assay, that analysis of the results obtained with (unpaired) BM and PB leukaemic cells from all 71 patients did not reveal a preferential resistance of the PB or BM leukaemic cells to any of the used drug. Similarly, no preferential resistance of the (paired) BM and PB leukaemic cells from 8 leukaemic patients (4 AML, 4 ALL) was found. The correlation for all 42 paired BM and PB LC 50 comparison was very good, with most pairs close to the ideal line (Fig. 1) . Our findings are in agreement with those of Kaspers et al. (1991) , who reported a significant association in resistance to a maximum of 14 drugs of leukaemic BM and PB cells from 12 patients. Finally, the comparable drug resistance profiles of leukaemic cells from the BM and those from the PB enables us to evaluate results using samples from both sources, which obviously is of practical importance.
The failure to cure leukaemia is probably due to the failure to eradicate the leukaemic clone. The mechanisms of drug resistance acting before the drug reaches its target (pharmacological resistance) and after the drug interacts with its target (cellular resistance) are gaining greater importance in understanding treatment failures (Minden et al. 1996) . The results of the present in vitro study suggest that AML in adults is a highly drug-resistant disease in comparison to ALL with respect to some drugs (dexamethasone, etoposide, prednisolone, vincristine) . The basis of the in vitro results between different diagnoses that may be caused by different biological aspects may also explain the difference in prognosis. We did not find significant differences in the in vitro testing of chemoresistance between the initial and relapse state of diseases, but higher variability of LC 50 values in leukaemic samples indicates the individual approach for in vivo chemotherapy. We also compared drug resistance (profiles) of different cytostatics among investigated diagnosis (Table 2) . These results suggest that the frequency of in vitro resistance to cytarabine, cladrabine, dacarbazin and doxorubicin are higher in acute lymphoblastic patients. However, patients with AML are more frequently resistant to dexamethasone, prednisolone and vincristine.
In conclusion, the MTT assay may be recommended as a sensitive tool for the prediction of clinical response to treatment of HMs. We hope that the application of this assay to leukaemic cells will help to predict prognosis and to plan optimal schedules for chemotherapy for individual patients. Drug resistance mechanisms contributing to treatment failure in acute leukaemia should be examined utilizing functional assays along with the determination of MDR protein in blasts either at the protein or mRNA level. The further classification of chemoresistance mechanisms will lead to the selection of circumvention strategies by specific resistance modifiers.
